• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Aria F. Olumi, MD


  • Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.5α-reductase inhibitors and risk of high-grade or lethal prostate cancer.JAMA Intern Med. 2014 Aug 1(8):1301-7.
  • Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT.Metformin Use and Prostate Cancer Risk.Eur Urol. 2014 May 21.
  • Bechis SK, Otsetov AG, Ge R, Olumi AF.Personalized Medicine for the Management of Benign Prostatic Hyperplasia.J Urol. 2014 Feb 25.
  • Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD.Prognostic significance of indeterminate lung nodules in renal cell carcinoma.Urol Oncol. 2014 Apr;32(3):355-61.
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA.Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.J Oncol Pract. 2014 Mar 1;10(2):107-12.
  • Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X.Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.Mol Cancer Res. 2014 Feb;12(2):217-27.
  • Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF.Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes.Urol Oncol. 2014 Jan;32(1):52.e19-25.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Models of care and NCCN guideline adherence in very-low-risk prostate cancer.J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.
  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder.N Engl J Med. 2013 Aug 15;369(7):660-7.
  • Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G.Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.Cancer Res. 2013 Jul 15;73(14):4429-38.
  • Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O.In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.Cell Metab. 2013 Mar 5;17(3):372-85.
  • Rodríguez D, Olumi AF.Management of spermatic cord tumors: a rare urologic malignancy.Ther Adv Urol. 2012 Dec;4(6):325-34.
  • Olumi AF.Editorial comment.J Urol. 2012 Dec;188(6):2107.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.J Clin Oncol. 2012 Sep 1;30(25):3071-6.
  • Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL.A close surgical margin after radical prostatectomy is an independent predictor of recurrence.J Urol. 2012 Jul;188(1):91-7.
  • Psutka SP, Feldman AS, Rodin D, Olumi AF, Wu CL, McDougal WS.Men With Organ-confined Prostate Cancer and Positive Surgical Margins Develop Biochemical Failure at a Similar Rate to Men With Extracapsular Extension.Urology. 2011 Mar 14.
  • Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF.Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy.Prostate. 2011 Feb 9.
  • Olumi AF.Editorial Comment.J Urol. 2009 May 16.
  • Olumi AF,Dewolf WC.The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste?.Urol Oncol. 2009 Mar-Apr;27(2):205-7.
  • Ganapathy M,Ghosh R,Jianping X,Zhang X,Bedolla R,Schoolfield J,Yeh IT,Troyer DA,Olumi AF,Kumar AP.Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.Clin Cancer Res. 2009 Mar 1;15(5):1601-11.
  • Zhang X,Huang X,Olumi AF.Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells.Int J Cancer. 2009 Apr 15;124(8):1980-9.
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM.MR imaging of renal masses: correlation with findings at surgery and pathologic analysis.Radiographics. 2008 Jul-Aug;28(4):985-1003. Review.
  • Zhang X, Li W, Olumi AF.Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.Clin Cancer Res. 2007 Dec 1;13(23):7181-90.
  • Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG.pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.Mol Cell. 2007 Oct 12;28(1):15-27.
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF.c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.Cancer Res. 2007 Oct 1;67(19):9425-34.
  • Huang X, Zhang X, Farahvash B, Olumi AF.Novel targeted pro-apoptotic agents for the treatment of prostate cancer.J Urol. 2007 Nov;178(5):1846-54. Review.
  • Li W, Wu CL, Febbo PG, Olumi AF.Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.Am J Pathol. 2007 Oct;171(4):1189-98.
  • Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG.HIF LINKED TO DIFFERENTIAL KIDNEY CANCER RISK SEEN WITH TYPE 2A AND TYPE 2B VHL MUTATIONS.Mol Cell Biol. 2007 Aug;27(15):5381-92.
  • Zhang L, Zhang X, Barrisford GW, Olumi AF.Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.Cancer Lett. 2007 Jun 18;251(1):146-57.
  • Li W, Zhang X, Olumi AF.MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L).Cancer Res. 2007 Mar 1;67(5):2247-55.
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF.Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.J Urol. 2006 Apr;175(4):1341-5; discussion 1345-6.
  • Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.Cancer Res. 2004 Oct 1;64(19):7086-91.
  • San Francisco IF, DeWolf WC, Peehl DM, Olumi AF.Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.Int J Cancer. 2004 Nov 1;112(2):213-8.
  • Olumi AF.Self-retraction clamp for dissection of the posterior prostatic fossa during radical retropubic prostatectomy.ScientificWorldJournal. 2004 Jun 7;4 Suppl 1:260-2.
  • San Francisco IF, Regan MM, Olumi AF, DeWolf WC.Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.J Urol. 2004 Apr;171(4):1492-9.
  • San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC.Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy.BJU Int. 2003 Dec;92(9):924-8.
  • Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF.The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection.J Urol. 2003 Jan;169(1):130-5.
  • Olumi AF, Richie JP, Schultz DJ, D'Amico AV.Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study.Urology. 2000 Aug 1;56(2):273-7.
  • Olumi AF.A critical analysis of the use of p53 as a marker for management of bladder cancer.Urol Clin North Am. 2000 Feb;27(1):75-82, ix.
  • Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR.Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.Cancer Res. 1999 Oct 1;59(19):5002-11.
  • Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP.Leydig cell hyperplasia mimicking testicular neoplasm.Urology. 1996 Oct;48(4):647-9.